On June 11, 2026 RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a patented, FDA-cleared drug-delivery device, reported the publication of a peer-reviewed case study from researchers at Moffitt Cancer Center was recently published in Radiology Case Reports.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The case study highlights potential optimization of the TAMP procedure with RenovoCath to deliver intra-arterial gemcitabine (a commonly used chemotherapy) directly near a tumor (rather than traditional systemic IV administration) in a patient with locally advanced pancreatic cancer (LAPC). Importantly, PET-CT imaging, rather than CT alone, showed a meaningful reduction in tumor metabolic activity after treatment, suggesting that PET may improve monitoring of therapeutic response following treatment delivered via TAMP.
The case study, titled "Trans-arterial gemcitabine micro perfusion of locally advanced pancreatic cancer enabled by coil plus glue embolization of a pancreaticoduodenal branch," was authored by Bela Kis, MD, PhD, and his colleagues at Moffitt Cancer Center and published in Radiology Case Reports. This is the first reported case in which physicians successfully embolized, or sealed off, a small branching artery using tiny coils and surgical glue to better optimize isolation of flow with TAMP-mediated gemcitabine delivered with RenovoCath during the same procedure.
The case study describes treatment of an 82-year-old patient with unresectable LAPC who underwent targeted intra-arterial gemcitabine treatment using TAMP following stereotactic body radiation therapy. During the procedure, physicians identified a pancreaticoduodenal artery (PDA) side branch that prevented optimal vessel isolation required for TAMP’s approach to pressure-mediated drug-delivery. Investigators subsequently performed coil plus glue embolization of the side branch, successfully enabling localized gemcitabine delivery via TAMP in the same procedural setting. The patient tolerated all 8 TAMP procedures (twice per month) without complications. Post eighth treatment at the 4-month follow-up, CT scans revealed stable disease (no change in tumor size) relative to scans performed prior to the first TAMP treatment, whereas PET-CT revealed a 52% reduction in tumor metabolic activity at the site of treatment.
"LAPC is already difficult-to-treat, and a pancreaticoduodenal artery (PDA) side branch adds another challenge to targeted therapy," said Bela Kis, MD, PhD, Moffitt Cancer Center and the first author of the case study. "TAMP uses RenovoCath, an innovative dual-balloon occlusion catheter designed to deliver therapy directly near tumors while reducing systemic exposure. The technology creates localized intra-arterial pressure that drives therapeutic agents across the vessel wall near the tumor."
Dr. Kis added, "We were encouraged by this case because the patient completed all eight RenovoCath-enabled TAMP treatments without complications. At the four-month follow-up, PET-CT imaging showed stable disease, while metabolic imaging indicated a positive treatment response, including a 52% reduction in fluorodeoxyglucose (FDG) activity at the treatment site."
"These findings further strengthen the growing body of peer-reviewed evidence supporting the procedural flexibility and targeted delivery capabilities of our TAMP therapy platform enabled by RenovoCath," said Ramtin Agah, MD, RenovoRx’s Chief Medical Officer, Executive Chairman, and Founder. "They also show how physicians may be able to address anatomical challenges to optimize targeted intra-arterial therapy, potentially increasing the therapeutic benefit of localized treatment options for patients with difficult-to-treat cancers."
Publication Details
Title: Trans-arterial gemcitabine micro perfusion of locally advanced pancreatic cancer enabled by coil plus glue embolization of a pancreaticoduodenal branch
Journal: Radiology Case Reports
DOI: View Source
Lead Author: Dr. Bela Kis, MD, PhD
Institution: Moffitt Cancer Center, Tampa, FL
About RenovoCath
Based on its FDA clearance, RenovoCath is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use ("IFU"), please see: IFU-10004-Rev.-G-Universal-IFU.pdf.
(Press release, Renovorx, JUN 11, 2026, View Source [SID1234666592])